Focused On-demand Library for Prominin-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O43490

UPID:

PROM1_HUMAN

Alternative names:

Antigen AC133; Prominin-like protein 1

Alternative UPACC:

O43490; Q6SV49; Q6SV50; Q6SV51; Q6SV52; Q6SV53; Q96EN6

Background:

Prominin-1, also known as Antigen AC133 and Prominin-like protein 1, plays a crucial role in cell differentiation, proliferation, and apoptosis. It binds cholesterol in plasma membrane microdomains, influencing the organization of the apical plasma membrane in epithelial cells. During retinal development, Prominin-1 is a key regulator of disk morphogenesis and is involved in the regulation of MAPK and Akt signaling pathways. In neuroblastoma cells, it suppresses differentiation, such as neurite outgrowth, in a RET-dependent manner.

Therapeutic significance:

Prominin-1 is implicated in several retinal dystrophies, including Retinitis pigmentosa 41, Cone-rod dystrophy 12, Stargardt disease 4, and Macular dystrophy, retinal, 2. These conditions highlight the protein's critical role in visual function and its potential as a target for therapeutic strategies aimed at treating retinal diseases.